Pages that link to "Q67773456"
Jump to navigation
Jump to search
The following pages link to The effect of measuring error on the results of therapeutic trials in advanced cancer (Q67773456):
Displaying 50 items.
- Inter-Method Performance Study of Tumor Volumetry Assessment on Computed Tomography Test-Retest Data (Q30993863) (← links)
- Volumes to learn: advancing therapeutics with innovative computed tomography image data analysis (Q33636321) (← links)
- Initial partial response and stable disease according to RECIST indicate similar survival for chemotherapeutical patients with advanced non-small cell lung cancer (Q33771180) (← links)
- The Role of Neoadjuvant Trials in Drug Development for Solid Tumors (Q33886353) (← links)
- Outcome assessment in cancer management (Q33931996) (← links)
- A pilot study of volume measurement as a method of tumor response evaluation to aid biomarker development (Q34134408) (← links)
- Tumor volume as an alternative response measurement for imatinib treated GIST patients (Q34469701) (← links)
- Reproducibility of tumor response evaluation in patients with high-grade malignant non-Hodgkin's lymphoma (Q34485458) (← links)
- Multiplexed PET Probes for Imaging Breast Cancer Early Response to VEGF121/rGel Treatment (Q34762148) (← links)
- Positron Emission Tomography (PET) in Oncology (Q34774840) (← links)
- From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors (Q34978457) (← links)
- Variability in assessing treatment response: metastatic colorectal cancer as a paradigm (Q35110520) (← links)
- Evaluation of RECIST in chemotherapy-treated lung cancer: the Pharmacogenoscan Study (Q35190735) (← links)
- Combination v. sequential therapy with melphalan, 5-fluorouracil and methotrexate for advanced ovarian cancer. (Q35228810) (← links)
- An approach for assessment of tumor volume from mammography in locally advanced breast cancer (Q35927233) (← links)
- The use of tumour volumetrics to assess response to therapy in anticancer clinical trials (Q36081423) (← links)
- How to study optimal timing of PET/CT for monitoring of cancer treatment (Q36337232) (← links)
- Comparative Effects of CT Imaging Measurement on RECIST End Points and Tumor Growth Kinetics Modeling (Q36599208) (← links)
- CA-125-indicated asymptomatic relapse confers survival benefit to ovarian cancer patients who underwent secondary cytoreduction surgery (Q36621252) (← links)
- A preclinical model for predicting drug response in soft-tissue sarcoma with targeted AAVP molecular imaging (Q36670260) (← links)
- Promises and challenges of positron emission tomography for assessment of sarcoma in daily clinical practice. (Q36971711) (← links)
- When progressive disease does not mean treatment failure: reconsidering the criteria for progression (Q37003248) (← links)
- Comparison of two-dimensional and three-dimensional iterative watershed segmentation methods in hepatic tumor volumetrics (Q37170295) (← links)
- Estimation of renal cell carcinoma treatment effects from disease progression modeling (Q37217573) (← links)
- Exploring intra- and inter-reader variability in uni-dimensional, bi-dimensional, and volumetric measurements of solid tumors on CT scans reconstructed at different slice intervals (Q37295117) (← links)
- Secondary cytoreduction surgery improves prognosis in platinum-sensitive recurrent ovarian cancer (Q37356602) (← links)
- Clinician-Reported Outcome Assessments of Treatment Benefit: Report of the ISPOR Clinical Outcome Assessment Emerging Good Practices Task Force (Q37737061) (← links)
- Recommendations of a group of experts for the pathological assessment of tumour regression of liver metastases of colorectal cancer and damage of non-tumour liver tissue after neoadjuvant therapy. (Q38135754) (← links)
- Patient-Reported Outcome Assessments as Endpoints in Studies in Infectious Diseases (Q39534931) (← links)
- Algorithm Variability in the Estimation of Lung Nodule Volume From Phantom CT Scans: Results of the QIBA 3A Public Challenge (Q39743075) (← links)
- Progress in chemotherapy for cancers of the urothelium (Q40173848) (← links)
- 'End-points in cancer therapy' the Glyn Evans memorial lecture of the Royal College of Radiologists (Q40282167) (← links)
- The clinical viewpoint: definitions, limitations of RECIST, practical considerations of measurement (Q40595362) (← links)
- How difficult is the validation of clinical biomarkers? (Q40650002) (← links)
- Measurement of tumor volumes improves RECIST-based response assessments in advanced lung cancer. (Q41206799) (← links)
- What does "response" in cancer chemotherapy really mean? (Q42352604) (← links)
- Surrogate endpoints (Q42390152) (← links)
- Accuracy of computerized tomography in determining hepatic tumor size in patients receiving liver transplantation or resection (Q42863961) (← links)
- Utility of fluorodeoxyglucose-positron emission tomography in the identification of new lesions in lung cancer patients for the assessment of therapy response (Q42868066) (← links)
- Response assessment after induction chemotherapy for head and neck squamous cell carcinoma: From physical examination to modern imaging techniques and beyond. (Q43234029) (← links)
- The initial change in tumor size predicts response and survival in patients with metastatic colorectal cancer treated with combination chemotherapy (Q43512983) (← links)
- Chemotherapy, Immunotherapy and Chemoimmunotherapy of Colorectal Cancer (Q44221353) (← links)
- Imaging in oncology: terms and definitions (Q44472578) (← links)
- Pattern of tumor progression in liver cancer: The missing partner in trial design. (Q50446050) (← links)
- Reproducibility of linear tumor measurements using PACS: comparison of caliper method with edge-tracing method. (Q52006961) (← links)
- Essentials of Statistical Methods for Assessing Reliability and Agreement in Quantitative Imaging. (Q52411957) (← links)
- Response rates--an evolution. (Q52882377) (← links)
- Tumour size measurement in an oncology clinical trial: comparison between off-site and on-site measurements. (Q52949841) (← links)
- Comparison of RECIST, EORTC criteria and PERCIST for evaluation of early response to chemotherapy in patients with non-small-cell lung cancer. (Q52982678) (← links)
- A Time to Keep and a Time to Cast Away Categories of Tumor Response (Q53215432) (← links)